Redmile Group, LLC 4

What Happened

• Redmile Group, LLC (a reported 10% owner) was granted a derivative stock option award for 87,900 shares of Fate Therapeutics (FATE) on June 12, 2026. The award shows a $0.00 acquisition price (i.e., a grant of options/rights rather than a cash purchase or sale).

Key Details

• Transaction date: 2026-06-12; Form 4 filed: 2026-06-15 (filed within the typical two-business-day window).
• Transaction type: A = Award/Grant of a derivative security (stock option) for 87,900 shares at $0.00.
• Vesting: The option vests in full on the earlier of (i) June 12, 2027 or (ii) the Issuer’s 2027 Annual Meeting, subject to Michael Lee’s continued board service (per footnote).
• Ownership after transaction: The filing does not state total shares/options held by Redmile after this grant.
• Reporting/beneficial ownership notes: Award was granted to Michael Lee as a nominee for Redmile; Mr. Lee assigned all economic/ voting rights to Redmile and disclaims beneficial ownership. The award may also be deemed beneficially owned by Jeremy Green (principal of Redmile); Redmile and Mr. Green disclaim ownership except to the extent of any pecuniary interest.
• Insider role: Michael Lee serves on the issuer’s board as Redmile’s representative (director by deputization).

Context

• This is an institutional director-related equity award (a grant of options), not an open-market buy or sale. Such awards compensate service and do not necessarily signal immediate buying or selling intent. The grant vests based on continued board service rather than immediate exercise; there is no cashless exercise or sale reported here.